Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230801 · ClinicalTrials.gov registry record · Phase 1
Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease
A Phase 1 study, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01230801 is a Phase 1 study that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 22 participants.
The verdict
NCT01230801, a Phase 1 study, has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
A Phase 1/2, open-label, multicenter, multiple dose escalation study of BMN 701 administered by intravenous infusion every 2 weeks over a 24-week treatment period to patients with late-onset Pompe disease.
Interventions
- BIOLOGICAL BMN 701
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2011-01-17 |
| Est. Completion | 2013-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230801
The ClinicalTrials.gov registry entry for NCT01230801 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMN 701 is the first listed.
NCT01230801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230801 about?
NCT01230801 is a clinical study titled "Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease". A Phase 1/2, open-label, multicenter, multiple dose escalation study of BMN 701 administered by intravenous infusion every 2 weeks over a 24-week treatment period to patients with late-onset Pompe disease.
What is the current status of trial NCT01230801?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2011-01-17. Estimated completion is 2013-03-06.
What interventions are being tested in trial NCT01230801?
The interventions under investigation include: BMN 701 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01230801?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.